Related Experiment Video

Updated: Aug 11, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

The current use of interferons, interleukin-2 and tumor necrosis factor in renal cell cancer

M Wirth1

  • 1Urologische Klinik und Poliklinik, Universität Würzburg, BRD.

Urologia Internationalis
|January 1, 1991
PubMed

Insights

Cytokine therapies, including interferons and interleukin-2, show limited success in treating advanced renal cell cancer. Combination therapy with low-dose interferon-alpha and interleukin-2 offers the best results with minimal patient harm.

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Cytokines like interferons, interleukin-2 (IL-2), and tumor necrosis factor have been explored for advanced renal cell cancer (RCC).
  • Objective remission rates (partial and complete) for cytokine therapy in RCC typically do not surpass 20%.
  • A complete cure for RCC using cytokine therapy has not been documented.

Purpose of the Study:

  • To evaluate the efficacy and safety of cytokine-based regimens in advanced renal cell cancer treatment.
  • To identify optimal cytokine combinations and dosages for managing advanced RCC.
  • To determine if cytokine therapy can achieve definitive cures in renal cell cancer patients.

Main Methods:

  • Review of existing literature on cytokine treatments for advanced renal cell cancer.
  • Analysis of objective remission rates (PR and CR) in patients treated with various cytokines.
  • Assessment of treatment-related morbidity associated with different cytokine regimens.

Main Results:

  • Cytokine therapies demonstrate disappointing objective remission rates, generally below 20% in advanced RCC.
  • No definitive cures for renal cell cancer have been reported with cytokine treatment alone.
  • Low-dose regimens combining interferon-alpha and interleukin-2 appear to yield the best outcomes with reduced patient morbidity.

Conclusions:

  • Current cytokine therapies offer limited efficacy for advanced renal cell cancer.
  • Combination therapy with low-dose interferon-alpha and interleukin-2 presents a promising approach for managing advanced RCC.
  • Further prospective trials are essential to define optimal treatment strategies and confirm the benefits of these cytokine regimens.

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...